Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in Asia

Abstract

<br /> <span style="font-size: small;">Cervical cancer is ranked the first or second most common cancer in women of low- and middle-income countries </span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">(LMICs) in Asia. Cervical cancer is almost exclusively caused by human papillomavirus (HPV), and majority of the </span></span><span style="font-size: small;">cases can be prevented with the use of HPV vaccines. The HPV vaccines have demonstrated high vaccine efficacies </span><span style="font-family: Times New Roman,Times New Roman; font-size: small;"><span style="font-family: Times New Roman,Times New Roman; font-size: small;">against HPV infection and cervical cancer precursors in clinical and post-marketing studies, and are in use in most high-income countries. However, their use in LMICs are limited mainly due to the high costs and logistics in delivering multiple doses of the vaccine. Other issues such as the safety of the vaccines, social and cultural factors, as well as poor knowledge and awareness of the virus have also contributed to the low uptake of the vaccine. This mini-review focuses on the need for HPV vaccine implementation in Asia given the substantial disease burden and underuse of HPV vaccines in LMICs in this region. In addition, the progress towards HPV vaccine introduction, and barriers preventing further rollout of these essential, life-saving vaccines are also discussed in this article. </span></span>